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Summary
Background: Both subcutaneous and sublingual allergen immunotherapy (SCIT and
SLIT) have been shown to effectively suppress allergic manifestations upon allergen
exposure, providing long-term relief from symptoms in allergic disorders including aller-
gic asthma. Clinical studies directly comparing SCIT and SLIT report a different kinetics
and magnitude of immunological changes induced during treatment. Comparative stud-
ies into the mechanisms underlying immune suppression in SCIT and SLIT are lacking.
Objective: We aimed to establish an experimental model for grass pollen (GP) SCIT
and SLIT that would allow a head-to-head comparison of the two treatments.
Methods: BALB/c mice were sensitized with GP extract, followed by SCIT and SLIT
treatments with various GP dosages. Subsequently, we challenged mice with GP
and measured airway responsiveness (AHR), GP-specific immunoglobulins, ear swel-
ling tests (EST), eosinophilic inflammation in bronchoalveolar lavage fluid (BALF),
and T cell cytokine release after restimulation of lung cells (IL-5, IL-10, and IL-13).
Results: We find that SLIT treatment was able to suppress allergen-induced AHR,
while allergic inflammation was not effectively suppressed even at the highest GP
dose in this model. In contrast, SCIT treatment induced higher levels of GP-specific
IgG1, while SLIT was superior in inducing a GP-specific IgG2a response, which was
associated with increased Th1 activity in lung tissue after SLIT, but not SCIT treat-
ment. Interestingly, SCIT was able to suppress Th2-type cytokine production in lung
cell suspensions, while SLIT failed to do so.
Conclusions and clinical relevance: In conclusion, GP-SCIT suppresses Th2 inflam-
mation and induced neutralizing antibodies, while GP-SLIT suppresses the clinically
relevant lung function parameters in an asthma mouse model, indicating that the
two application routes depend on partially divergent mechanisms of tolerance
induction. Interestingly, these data mirror observations in clinical studies, underscor-
ing the translational value of these mouse models.
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1 | INTRODUCTION
To successfully treat allergic airway disease, international guidelines
recommend allergen-specific immunotherapy (AIT).1,2 Administration
of allergen extracts via the subcutaneous (SCIT) and sublingual (SLIT)
route has both been found to be effective therapies. For instance,
SCIT treatment with grass pollen (GP) or house dust mite has shown
clinical success in restoring long-term allergen-specific tolerance.3,4 In
a double-blinded, randomized placebo-controlled trial (RCT) in patients
with allergic rhinoconjunctivitis, GP-SLIT treatment was also found to
induce a significant and durable induction of neutralizing antibody
responses as well as decreased symptom score up to 2 years after
completion of a 3-year treatment period.5 Moreover, a recent meta-
analysis comparing SLIT tablets, SLIT drops, and SCIT injections for GP
allergies reported comparable reduction in symptom scores and sup-
plemental medication use for SLIT tablets and SCIT injections.6
Recent studies comparing SCIT and SLIT have reported differences
in the kinetics and magnitude of immunological changes induced by
these treatments.7-12 For instance, Aasbjerg et al directly compared
GP-SCIT vs GP-SLIT treatment in patients with allergic rhinitis and
found both treatments to be effective compared to placebo con-
trols.8,13 SCIT treatment induced twofold to threefold greater induc-
tion of specific IgG4, while the effects on facilitated antigen
presentation and basophil sensitivity induced by SCIT treatment were
more pronounced in the first few months of treatment.8 Moreover,
SCIT, but not SLIT, treatment induced suppression of IL-5 production
by CD4+ T cells.13 While an initial meta-analysis reported that SCIT
was more effective in symptom control and reduction in medication,14
a more recent study provided indirect evidence that SCIT and SLIT
have a similar efficacy for the treatment of allergy.6 Patients have been
reported to show a preference for SLIT over SCIT.15
The mechanism of action for successful specific immunotherapy,
irrespective of administration route, is thought to involve induction
of neutralizing antibodies, an increased activity of regulatory T cells
characterized by IL-10 production, and a gradual decline in specific
IgE. The mechanisms underlying clinical efficacy in either SCIT or
SLIT and the exact differences between the two treatments are not
fully characterized. In clinical studies, immunological comparison of
SCIT and SLIT is hampered by the limited amount of data from
head-to-head comparisons and by the variability of the end-points
used between studies.9 Consequently, it remains unknown whether
the differences in the immunological changes induced by SCIT and
SLIT are relevant to clinical efficacy of either treatment.8,9,16,17
We have previously used experimental models of allergic airway
disease to characterize critical immunological mechanisms underlying
the mode of action of AIT.18,19 Therefore, in this study, we aimed to
establish an experimental model for GP-SCIT and GP-SLIT that
allows direct comparison of the two treatments, to characterize the
immunological changes and suppression of clinically relevant out-
come parameters induced by either treatment as a platform to test
further optimization of either form of AIT.
2 | METHODS
2.1 | Animals
BALB/cByJ mice (8-9 weeks old) were purchased from Charles River
(L’Arbresle, France) and bred in individually ventilated cages and fed
a hypoallergen GP-free diet (4 kcal/gr, 25% protein, 11% fat, 47%
sugars, 5% fibres; AB Diets, Woerden, The Netherlands). Female 7-
9-week-old progeny on the same diet were used for the experiments
(8 mice/group). The Institutional Animal Care and Use Committee at
the University of Groningen approved experiments.
2.2 | Allergic asthma and treatment protocols
All mice received two intraperitoneal injections of 5000 standardized
quality (SQ) units (5kSQ = 8 lg allergen extract of GP (Phleum pra-
tense, Phl p; ALK-Abello, Hørsholm, Denmark) adsorbed to 1.6 mg
Alum (Imject Alum, Pierce, USA) in 100 lL Phosphate-buffered Sal-
ine (PBS, Figures 1A,B, and 4A,B). SCIT was performed by three
100 lL injections or SLIT was performed by 40 5 lL sublingual
administrations.20 Inhalation challenges were administered as dro-
plets of 25kSQ GP in 25 lL PBS after light isoflurane anaesthesia.
After 2 days, airway responsiveness was determined, and serum
samples, bronchoalveolar lavage fluid (BALF), and lung lobes were
stored for further analyses (80°C).
2.3 | Early-phase hypersensitivity: the EST
Similarly, as the skin prick test used in the clinic, we used ear swelling
tests (ESTs), which were performed 1 week prior to AIT, to confirm a
GP-specific response and 10 days thereafter to evaluate suppression
of swelling (Figure 1A and 4A). Herein, 1kSQ GP in 10 lL PBS was
injected intradermally in the right ear of anaesthetized mice, while as a
control, 10 lL PBS was injected in the left ear.21,22 After two hours,
thickness was measured using a force micrometer at 0.5N (0.15N,
Mitutoyo, Japan). The net thickness (D, lm) was calculated by sub-
tracting the thickness of the left from the right ear.
2.4 | Evaluation of Airway hyperresponsiveness
Airway responsiveness was assessed 48 hours after the last chal-
lenge by measuring airway resistance (R in cmH2O.s/mL) and lung















































































































Group Sensitization SCIT Challenge
NC 5 kSQ/Alum PBS PBS
PC 5 kSQ/Alum PBS 25 kSQ
SCIT 30 5 kSQ/Alum 30 kSQ 25 kSQ
SCIT 100 5 kSQ/Alum 100 kSQ 25 kSQ
SCIT 300 5 kSQ/Alum 300 kSQ 25 kSQ
(D)




































































F IGURE 1 Overview and immunoglobulin response after GP-SCIT treatment. A, Outline of the SCIT protocol. B, Outline of the treatment
groups. C, Serum total IgE (ng/mL) taken before SCIT (white bars, Pre1), before challenge (grey bars, Pre2), and after challenges (black bars,
Post). D, Serum GP-spIgE (Arbitrary Units (AU)/mL, Pre2, and Post). E, Serum GP-spIgG1 (AU/mL, Pre1-2, and Post). F, Serum GP-spIgG2a
(AU/mL, Pre1-2, and Post). G, Neutralizing activity plotted as ratio of GP-spIgG1/GP-spIgE levels in Pre2-sera. H, Neutralizing activity plotted
as ratio of GP-spIgG2a/GP-spIgE levels in Pre2-sera. I, Fold induction of GP-spIgE after challenge (Post-sera/Pre2-sera). In Figure 1C-F, values
are expressed as mean  SEM (n = 8). In Figure 1G-I, values are expressed in box-and-whiskers plots (min-max). *P < .05, **P < .01, and
***P < .005 compared to PC at the same time-point. NC: negative control, PBS challenged; PC: positive control, GP challenged; 30, 100, 300:
different doses of SCIT-treated mice (kSQ), GP challenged
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compliance (C in mL/H2O) in response to intravenous administration
of increasing doses of methacholine (Sigma-Aldrich, MO) using a
computer-controlled small animal ventilator (FlexiVent; SCIREQ,
Quebec).23
2.5 | Evaluating inflammation in BALF
Directly after the AHR measurements, the lungs were lavaged and
cytospin preparations were made according to the previous pub-
lished protocols.24
2.6 | Analysis of T cell responses: restimulation of
lung single cell suspensions
Lung single cell suspensions (5x105/well) were stimulated (in triplo)
for 5 days in supplemented RPMI1640 with 0 lg or 30 lg GP/
well. Supernatant was stored in triplo (80°C), for ELISA measure-
ments of IL-5, IL-10, IL-13, IFNc, and TGFb1 according to the
manufacturer’s instructions (R&D Systems, Bio-Techne). The lower
detection limits of the ELISAs were 3 pg/mL for IL-5, 10 pg/mL
for IL-10, 15 pg/mL for IL-13, 30 pg/mL for IFNc, and 30 pg/mL
for TGFb1.
2.7 | Measurement of GP-specific Immunoglobulins
in serum
Blood was collected in MiniCollect Serum Tubes (Greiner Bio-One,
Alphen a/d Rijn, The Netherlands) via orbital puncture (pre-sera) and
after the FlexiVent via the vena cava inferior (post-sera, Figure 1A,B,
and 4A,B). Grass pollen-specific IgE (GP-spIgE), GP-spIgG1, and GP-
spIgG2a levels were measured by ELISA as described previously in
all collected sera samples.25-27
2.8 | Statistical analyses
All data were expressed as means  SEMs. The Mann-Whitney U
Test was used to analyse the results, and P < .05 was considered
significant. Within the ELISA data, an AU value which was more than
three times the interquartile (IQ) range higher than the upper Q or
more than three times the IQ range lower than the lower Q was
considered to be an extreme outlier and was removed for further
analysis. Within the AHR measurements, a generalized estimated
equation (GEE) analysis was used, using SPSS Statistics 20.0.0.2.28
Nonparametric Spearman correlations were performed in Fig-
ure S4A-F.
See additional Methods description in the Data S1.
3 | RESULTS
3.1 | Serum immunoglobulin levels in GP-SCIT
To study the efficacy of GP-SCIT for suppression of asthmatic
manifestations upon intranasal GP challenges, we started with a
dose-finding experiment in which three doses GP extract (30, 100,
or 300kSQ) were included for SCIT treatment (Figure 1A,B). To
examine whether SCIT affected GP-specific serum immunoglobulin
responses, we measured total IgE, GP-spIgE, GP-spIgG1, and GP-
spIgG2a in serum taken at different time-points: after sensitization
(white, Pre1), after SCIT treatment (grey, Pre2) and after the chal-
lenges (black, Post). Compared to the PBS-SCIT group, GP-SCIT
injections resulted in significantly increased levels of total IgE
(Figure 1C), that did not show a significant further increase after
subsequent GP challenges. Furthermore, after GP-SCIT treatment
the levels of GP-spIgE, GP-spIgG1 levels, as well as GP-spIgG2a
were significantly increased as compared to PBS-SCIT-treated
controls (PC, Figure 1D,E,F).
After the GP challenges, although not significant, we observed a
slight dose-dependent decrease in serum levels of GP-spIgE, which
implies an inverse correlation between GP dose in SCIT and spIgE in
serum after challenges (Figure 1D). Interestingly, GP-spIgG1 levels
after the GP challenges were significantly increased in the 300kSQ
GP-SCIT treatment group (Figure 1E), compared to the sham-treated,
GP-challenged asthma control group (PC).
As a measure of neutralizing capacity after GP-SCIT, the ratios of
GP-spIgG1/GP-spIgE levels and GP-spIgG2a/GP-spIgE levels showed
significant increases as compared to the PBS-SCIT-treated group
(PC, Figure 1G,H). In contrast, when establishing fold inductions of
GP-spIgE levels after GP challenges (GP-spIgE post/Pre2), we did
not find significant reduction in the GP-SCIT-treated groups as com-
pared to the positive controls (Figure 1I).
Overall, these results indicate GP-SCIT treatment induces a
strong GP-spIgG1 and GP-spIgG2a response, while the use of three
subcutaneous injections increased GP-spIgE serum levels after treat-
ment and prevented further induction of spIgE after subsequent
allergen challenges.
3.2 | Suppression of ear swelling and airway
responsiveness after GP-SCIT
In the EST, we measured the net ear swelling (right ear minus left
ear) two hours after intradermal GP injection at two time-points
in our experimental protocol (Figure 1A). As expected, all experi-
mental groups showed a net increase in ear swelling 1 week after
the last GP/Alum injection (Figure S1A). After GP-SCIT, we
observed a positive EST in all GP sensitized, placebo-treated con-
trol mice, similar to the EST after sensitization only (plotted
together as Controls, Figure 2A). This EST showed a significant
decrease in the 300kSQ GP-SCIT-treated group as compared to
the sensitized controls (74.9  12.3 vs 117.4  10.4, Figure 2A).
Similar results were found when plotting ratios of the EST value/
average of the controls to allow intertreatment comparison
(Figure S1C).
In addition, we measured methacholine-induced airway hyper-
responsiveness in all experimental groups. We observed marked
AHR in the PBS-SCIT, GP-challenged mice (PC) as compared to
the PBS-SCIT, PBS challenged mice (NC; Figure 2C). Administering
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the highest dose of GP-SCIT provided a trend to suppression of
the dose-response curve of the airway resistance (P = .062, Fig-
ure 2C). In testing the effect of GP-SCIT on the suppression of
this response, we found that the effective dose (ED) of metha-
choline necessary to increase AHR to an R of 3 cmH2O.s/mL
(ED3) was significantly increased in the 300kSQ GP-SCIT group as
compared to the sham-treated control group (Figure 2B). Identical
results can be found when testing for differences in ratio of ED3/
average of ED3 of PC (Figure S1E). Remarkably, in examining the
comparative stiffness of the lung, compliance values showed no
significant differences between any of the experimental groups as
compared to the PBS-SCIT-treated positive control group
(Figure 2D).
Altogether, the decrease in EST, increase in ED3 and trend
towards a reduced airway resistance showed that the highest dose
of GP administered in a SCIT protocol actively suppresses the
asthmatic manifestations in this experimental immunotherapy
protocol.
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F IGURE 2 Clinical manifestations after GP-SCIT treatment. A, IgE-dependent allergic response plotted as net ear thickness (lm) two
hours after GP injection (1kSQ) in the right ear and PBS in the left ear as a control, performed after SCIT. Placebo-SCIT-treated mice
were plotted together as Controls (NC and PC). B, Effective dose (ED) of methacholine, when the airway resistance reaches 3 cmH2O.s/
mL (ED3). C, Airway hyperreactivity (AHR) was measured by FlexiVent and plotted as airway resistance (R in cmH2O.s/mL) and as D,
airway compliance (C in mL/cmH2O). Absolute values are expressed as mean  SEM (n = 8). *P < .05, **P < .01, and ***P < .005
compared to PC. NC, negative control, PBS challenged; PC, positive control, GP challenged; 30, 100, 300: different doses of SCIT (kSQ),
GP challenged
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3.3 | SCIT suppresses of eosinophilic airway
inflammation and cytokine levels
To evaluate the suppression of airway inflammation and Th2 cell activ-
ity after GP-SCIT, we measured inflammatory cell numbers in BALF
and Th2 cytokines in restimulated lung cells. Within the GP-SCIT
groups, we observed a dose-dependent decrease wherein the highest
dose of SCIT resulted in a significant decrease in total cell count (Fig-
ure 3A). Next, we analysed numbers of mononuclear cells (M), eosino-
phils (E), and neutrophils (N) in BALF and single cell suspensions of
lung tissue in the GP-SCIT groups and found a marked dose-depen-
dent decrease in numbers of eosinophils in BALF as compared to the
PBS-treated GP-challenged group (Figure 3B). The counts in lung sin-
gle cell suspensions are comparable, in that the 100kSQ and 300kSQ
groups showed significantly decreased numbers of eosinophils as com-
pared to the PBS-SCIT, GP-challenged mice (Figure 3C). To clarify,
both eosinophil counts were included as dot plots in Figure S2A,B. To
allow for intertreatment comparison, the eosinophils found in BALF
and lungs showed identical significance when plotted as ratio of eosi-
nophil count divided by the average eosinophil count in the PBS-SCIT-
treated positive controls (Figure 3D,E).
Next, we analysed cytokine release in the supernatant of GP-sti-
mulated lung single cell suspensions and observed a significant sup-
pression of IL-13 levels (Figure 4F), while the highest dose of SCIT
showed a trend towards reduced IL-5 levels, but failed to reach sig-
nificance (P = .052, Figure 4F). Interestingly, GP stimulation of lung
cells from all SCIT groups failed to induce an enhanced IL-10 pro-
duction. GP-SCIT did not alter the Th2 cytokine profile leading to
enhanced Th1 cell IFNc production.
In addition, we measured IL-5, IL-10, and TGFb1 levels in lung
tissue homogenates, which resulted in a significant IL-5 suppression
after high dose GP-SCIT (Figure S3A). Similarly, as with the restimu-
lated lung cells, SCIT failed to induce enhanced production of IL-10
and TGFb1 (Figure S3C,E).
Overall, we observed a reduced eosinophilic airway inflammation
in BALF and lung cells and decreased production of the prototypic Th2
cytokine IL-13 in response to GP stimulation in GP-SCIT-treated mice.
3.4 | Serum immunoglobulin responses induced by
GP-SLIT
Next, we sought to evaluate the optimal dosage of GP for sublingual
application in the experimental mouse model of allergic airway dis-
ease (Figure 4A,B). Serum was taken at five time-points for determi-
nation of total- and GP-specific immunoglobulin levels. In sera taken
3 weeks after starting GP-SLIT, we observed a marked increase in
total IgE (Figure 4C) and GP-spIgE (Figure 4D). After GP challenges,
PBS-SLIT control mice exhibit a strong GP-spIgE response. In con-
trast, GP-SLIT-treated groups showed a limited (30kSQ) or no (100/
300kSQ) further induction of spIgE by the challenges after comple-
tion of the SLIT treatment protocol. In the 100 and 300kSQ SLIT
groups, GP-spIgE serum levels were significantly reduced after the
final GP challenges as compared to the sham-treated controls.
Additionally, significant increases of GP-spIgG1 were observed
after 6 weeks of treatment onwards in the 100kSQ and 300kSQ GP-
SLIT groups as compared to the sham-treated mice at the same time-
point (Figure 4E). GP-spIgG1 levels did not further increase after GP
challenges in GP-SLIT-treated groups, while challenges induced a
marked increase in GP-spIgG1 responses in the PBS-treated control
group. In contrast, GP-spIgG2a levels in the GP-SLIT-treated mice
were significantly induced after GP challenges (Figure 4F).
Next, we calculated the neutralizing activity after GP-SLIT treat-
ments in ratios of GP-spIgG1/GP-spIgE levels (not significant) and
ratios of GP-spIgG2a/GP-spIgE levels, in which the latter showed
significant increases as compared to the PBS-SCIT-treated group
(Figure 4G,H). Furthermore, in contrast to the GP-SCIT treatments,
the fold inductions of GP-spIgE levels after GP challenges (GP-spIgE
post/Pre2 sera), showed a significant decrease as compared to the
positive controls (Figure 4I).
These data indicate that GP-SLIT treatment induced increased
specific immunoglobulin responses while providing a significant
decrease in GP-spIgE by subsequent GP challenges.
3.5 | GP-SLIT reduces ear swelling and
hyperresponsiveness
Next, we assessed whether the early-phase response to intradermal
grass pollen challenge in the ear was suppressed in GP-SLIT-treated
mice. Increasing doses of GP-SLIT resulted in a progressive reduction
in the GP-induced ear swelling, reaching statistical significance only
in the highest SLIT dose when compared to the PBS-treated control
group (80  15.9 vs 141.7  12.7, Figure 5A). Similar results were
found when plotting ratios of the EST value/average of the controls
to allow intertreatment comparison (Figure S1B).
To measure the effect of GP-SLIT treatment on translational
parameter of AHR to methacholine, we measured airway resistance
(R) and compliance (C) in all experimental groups (Figure 5C,D). GP-
challenged mice that had received PBS-SLIT treatment (PC) showed
a marked increase in airway resistance as compared to the PBS chal-
lenged mice that had received PBS-SLIT treatment (NC; Figure 5C).
Interestingly, we observed a strong reduction in the methacholine
dose-dependent airway resistance in the 300kSQ GP-SLIT group as
compared to the sham-treated positive controls. In addition, the ED3
values (R of 3 cmH2O.s/mL) of the GP-SLIT mice treated with the
highest dose of GP (300kSQ) confirmed a significantly reduced sensi-
tivity to methacholine (Figure 5B). Identical results were obtained
when calculating the ratio of ED3/average of ED3 in the positive
controls to allow efficient comparison between groups (Figure S1F).
Finally, our data revealed a strong trend towards increased lung
compliance for the highest SLIT group (P = .057, Figure 5D).
In all, the progressive decrease in ear swelling upon higher
dosages of GP-SLIT, the significantly reduced airway resistance in
response to methacholine challenges and the strong trend in
increased compliance showed that the highest GP-SLIT dose
(300kSQ) successfully suppresses the asthmatic manifestations in
this experimental immunotherapy protocol.





















































































NC PC 30 100 300
BALF 1,59 ± 0,3*** 15,1 ± 1,7 15,5 ± 0,5 11,9 ± 2,0 0,09 8,74 ± 2,6*
Lung 8,55 ± 1,3*** 27,2 ± 3,0 31,0 ± 3,1 23,2 ± 1,9 17,7 ± 2,1*
Total Cell Count SCIT
SCIT SCIT
SCIT SCIT
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F IGURE 3 The eosinophilic and cytokine response after GP-SCIT treatment. A, Total cell counts in bronchoalveolar fluid (BALF) and lung single cell
suspensions (Lung). B, Differential cytospin cell counts in BALF and in C, lung. M, mononuclear cells; E, eosinophils; N, neutrophils. Absolute numbers
are plotted in box-and-whiskers plots (min-max). D, BALF eosinophils and E, lung eosinophils, both plotted as ratio of suppression (absolute
eosinophils/average PC eosinophils; mean  SEM). F: Net levels of IL-5, IL-10, IL-13, and IFNcmeasured in restimulated lung single cell suspensions.
Concentrations were calculated as the concentration after restimulation minus control (mean  SEM, n = 8). *P < .05, **P < .01, and ***P < .005
compared to PC. NC: negative control, PBS challenged; PC: positive control, GP challenged; 30, 100, 300: different doses of SCIT (kSQ), GP challenged
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Group Sensitization SLIT Challenge
NC 5 kSQ/Alum PBS PBS
PC 5 kSQ/Alum PBS 25 kSQ
SLIT 30 5 kSQ/Alum 30 kSQ 25 kSQ
SLIT 100 5 kSQ/Alum 100 kSQ 25 kSQ
SLIT 300 5 kSQ/Alum 300 kSQ 25 kSQ
1
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F IGURE 4 Overview and immunoglobulin response after GP-SLIT treatment. A, Outline of the SLIT protocol. B, Outline of the treatment groups.
C, Serum levels of total IgE (ng/mL) taken before SLIT (white bars, Pre1), after 3 weeks of SLIT (light grey bars, Pre2), after 6 weeks of SLIT (middle
grey bars, Pre3), before challenge (dark grey bars, Pre4), and after challenges (black bars, Post). D, Serum GP-spIgE (Arbitrary Units (AU)/mL, Pre1-4,
and Post). E, Serum GP-spIgG1 (AU/mL, Pre1-4, and Post). F, Serum GP-spIgG2a (AU/mL, Pre1-4, and Post). G, Neutralizing activity plotted as ratio
of GP-spIgG1/GP-spIgE levels in Pre4-sera. H, Neutralizing activity plotted as ratio of GP-spIgG2a/GP-spIgE levels in Pre4-sera. I, Fold induction of
GP-spIgE after challenge (Post-sera/Pre4-sera). In Figure 4C-F, values are expressed as mean  SEM (n = 8). In Figure 4G-I, values are expressed in
box-and-whiskers plots (min-max). *P < .05, **P < .01, and ***P < .005 compared to positive control at the same time-point. NC: negative control,
PBS challenged; PC: positive control, GP challenged; 30, 100, 300: different doses of SCIT-treated mice (kSQ), GP challenged
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3.6 | Effects of GP-SLIT on eosinophilic
inflammation and cytokine responses
To assess the effect of GP-SLIT on suppression of airway inflamma-
tion, we compared the eosinophilic airway inflammation and evaluated
Th2 cytokines in restimulated lung cell homogenates of GP-SLIT-trea-
ted mice. We found that the numbers of eosinophilic granulocytes in
BALF were comparable between GP-SLIT-treated mice and PBS-SLIT
control-treated mice (Figure 6A,B). In contrast, differential cell counts
in lung single cell suspensions revealed significantly decreased num-
bers of eosinophils in all GP-SLIT-treated groups as compared to the
PBS-treated control group (Figure 6C and Figure S2C,D). Also when
expressed as fold reduction in eosinophils compared to PBS-SLIT
group, allowing straightforward comparisons between the groups, sig-
nificantly, reductions in eosinophils in lung tissue, but not in BALF,
were observed in all experimental groups (Figure 6D,E).
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F IGURE 5 Clinical manifestations after GP-SLIT treatment. A, IgE-dependent allergic response plotted as net ear thickness (lm) 2 hours
after GP injection (1kSQ) in the right ear and PBS in the left ear as a control, performed after SLIT. Placebo-SLIT-treated mice were plotted
together as Controls (NC and PC). B, Effective dose (ED) of methacholine, when the airway resistance reaches 3 cmH2O.s/mL (ED3). C: Airway
hyperreactivity (AHR) was measured by FlexiVent and plotted as airway resistance (R in cmH2O.s/mL) and as D: airway compliance (C in mL/
cmH2O). Absolute values are expressed as mean  SEM (n = 8). *P < .05, **P < .01, and ***P < .005 compared to PC. NC: negative control,
PBS challenged; PC: positive control, GP challenged; 30, 100, 300: different doses of SLIT-treated mice (kSQ), GP challenged
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To evaluate the effect of GP-SLIT on Th2 cell driven inflamma-
tion, we measured cytokine levels in the supernatant of lung cells
restimulated with GP ex vivo. In PBS-treated GP-challenged mice,
we observed high levels of IL-5, IL-10, and IL-13, while IFNc levels
decreased compared to cultures from PBS challenged mice (Fig-
ure 6F). Remarkably, GP-SLIT treatment did not affect the cytokine
production after GP stimulation of lung cells. However, we measured
IL-5, IL-10, and TGFb1 levels in lung tissue homogenates, which
resulted in a trend towards IL-5 suppression after high dose GP-SLIT
(Figure S3B). Comparable to our restimulated cell cytokine produc-
tion and the SCIT model, SLIT failed to induce enhanced production
of IL-10 and TGFb1 (Figure S3D,F).
In conclusion, we observed reduced numbers of eosinophilic
granulocytes in lung cell suspensions but not in BAL of all GP-SLIT-
treated mice. Although none of the Th2 cytokines measured in
supernatant of ex vivo restimulated lung cells were significantly
reduced after GP-SLIT treatment, high dose GP-SLIT did result in a
trend towards suppression of IL-5 in the lung tissue homogenates.
3.7 | Comparing GP-SCIT and GP-SLIT
Altogether, we can conclude that both administrative routes render
suppression of certain phenotypes of the experimental mouse model
of GP-driven allergic asthma. To allow quantitative evaluation of the
relative efficacy of either administration route of GP-AIT on the vari-
ous parameters of the allergic asthma mouse model, we provide an
overview of all parameters measured in Table 1. To start, the
immunoglobulin responses showed marked differences: the total and
specific IgE responses measured after GP challenges were in the
same range in SCIT as well as SLIT. The fold induction of IgE after
GP challenges, however, was far more effectively suppressed by GP-
SLIT (SCIT: 11,7-fold induction of IgE (vs 49,6) and SLIT 2,4 (vs
25,4), Table 1). The blocking immunoglobulins differ based on iso-
type: GP-spIgG1 is superior in the (faster) SCIT protocol, while the
IgG2a levels are higher after SLIT treatment. Consequently, as
expressed by the comparison of the median of the 300kSQ group of
both administrative routes (Table 1), the neutralizing capacity by
IgG1 (78x106 AU/mL) was much better in SCIT than in SLIT (39x106
AU/mL), while the opposite accounts for the IgG2a measurements
(SCIT, 430 AU/mL vs. SLIT 220 9 103 AU/mL).
When comparing the airway resistance, GP-SLIT showed a signif-
icant reduction, while the highest dose of GP-SCIT merely provided
a trend towards suppression of AHR (Figure 2C and 5C). This differ-
ence is further highlighted when calculating the fold reduction in
resistance at 400 lg/kg MCh vs the average of the positive controls,
results showed more than twice the reduction rate in SLIT as com-
pared to SCIT treatments (0924 vs 2712, Table 1). Moreover, only
SLIT treatment was able to provide a trend in increased compliance
values (P = .052, Figure 5D), while SCIT was unable to improve com-
pliance even at the highest dose of GP (Figure 2D).
In contrast, when comparing eosinophilic inflammation in BALF
and Lung, marked responses can be detected in the SCIT protocol
(suppression of 4386 vs PC in BALF), while in SLIT these findings
were less profound (suppression of 2018 vs PC, Table 1). These
findings are accompanied by an increased Th1 activity in lung tissue
after SLIT (P = .06, Figure 6F), but not SCIT treatment. Interestingly,
SCIT was able to suppress IL-13 production by lung cells, while SLIT
failed to do so (Figure 3F). Although not equally strong, both admin-
istrative routes showed reduced levels of IL-5 in lung tissue
homogenates.
Next, we asked whether the levels of GP-specific neutralizing
antibodies after SCIT and SLIT correlated with a decreased AHR or
immunological response after GP challenges. Here, we found a nega-
tive correlation between GP-spIgG1 (Post-SCIT) vs eosinophils in
BALF and IL-5 in both administrative routes, whereas GP-spIgG1
correlated significantly with IL13 only after SLIT (Figure S4A-F).
4 | DISCUSSION
We aimed to establish an experimental mouse asthma model allow-
ing direct comparison of GP-SCIT and SLIT to identify the opportuni-
ties for improvement of these treatment modalities. The results of
this study clearly demonstrate that GP-SCIT and GP-SLIT can both
suppress specific parameters of GP-induced allergic airway inflamma-
tion. However, there are marked differences in the efficacy of either
treatment towards specific outcome parameters. We find that GP-
SCIT treatment mainly modulated the allergen-specific adaptive
immune response, with reduced Th2 inflammation and airway
eosinophilia, and increased levels of spIgG1 and spIgG2a. In contrast,
GP-SLIT treatment mainly affected lung function parameters, with
significantly suppressed airway hyperresponsiveness and a trend
towards improved lung compliance, while Th2 cytokines and eosino-
phil numbers in BALF were not markedly affected, while eosinophils
in lung tissue were suppressed. Also, GP-SLIT treatment did not
induce markedly increased levels of neutralizing antibodies, while
spIgE levels were decreased. Of note, SCIT treatment did induce a
trend towards suppression of AHR, indicating that with a larger
group size this effect might have become statistically significant as
well. Notwithstanding, the effect size of SLIT on AHR was stronger
F IGURE 6 The eosinophilic and cytokine response after GP-SLIT treatment. A, Total cell counts in bronchoalveolar fluid (BALF) and lung
single cell suspensions (Lung). B, Differential cytospin cell counts in BALF and in C, lung. M, mononuclear cells; E, eosinophils; N, neutrophils.
Absolute numbers are plotted in box-and-whiskers plots (min-max). D, BALF eosinophils and E, lung eosinophils, both plotted as ratio of
suppression (absolute eosinophils/average PC eosinophils; mean  SEM). F: Net levels of IL-5, IL-10, IL-13, and IFNc measured in restimulated
lung single cell suspensions. Concentrations were calculated as the concentration after restimulation minus control (mean  SEM, n = 8).
*P < .05, **P < .01, and ***P < .001 compared to PC. NC, negative control, PBS challenged; PC, positive control, GP challenged; 30, 100, 300:
different doses of SLIT (kSQ), GP challenged
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BALF 1,56 ± 0,1*** 8,49 ± 0,8 10,3 ± 1,6 8,42 ± 1,3 10,2 ± 1,6
Lung 10,7 ± 0,7*** 18,9 ± 1,3 14,7 ± 2,4 19,0 ± 1,8 16,7 ± 1,8*
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than that of SCIT. For full suppression of AHR, a further increase in
SCIT dose or a more chronic application of SCIT might be warranted.
Conversely, the effect size of SCIT on suppression of Th2 cytokines
and eosinophilic airway inflammation was stronger than that of SLIT,
indicating that a higher allergen dose in SLIT, or a modified delivery
method, might be warranted for full efficacy. Overall, these data
indicate that the route of administration of a therapeutic GP vaccine
in an experimental model for AIT plays a major role in determining
the efficacy of the treatment towards suppressing specific parame-
ters of the experimental asthma model.
In this initial study, we did not assess into great detail the biolog-
ical mechanisms underlying the differences in the efficacy of SCIT vs
SLIT mediated suppression of parameters of allergic airway
inflammation in our experimental mouse model. The main differences
are the route of allergen administration, the duration of treatment
and the amount of allergen administered. Whereas SCIT relies on
direct injection of high doses of allergen for a short duration, SLIT
relies on sublingual application of lower amounts of allergen for a
prolonged period. This will first of all affect the antigen-presenting
cell population responsible for allergen presentation to the available
memory T cell population in the draining lymph nodes. SLIT has been
shown to mainly target oral CD11b+CD11c cells, which have a
strong tolerogenic capacity.29 In contrast, SCIT injection mainly
induces allergen presentation by mPDCA+ CD11c+ plasmacytoid
dendritic cells (our unpublished observations). The difference in the
antigen-presenting cell subset between the two administration
routes might contribute to efficacy of immune modulation between
the two treatment options. In addition, the dose of allergen in the
SCIT treatment protocol is much higher per administration, which
likely results in a higher number of na€ıve T cells activated (in a
tolerogenic fashion) after the SCIT injections compared to the SLIT
administration, where antigen presentation and therefore immune
modulation will likely be restricted to antigen-experienced memory T
cells. The mechanistic details underlying SCIT and SLIT are therefore
an important subject for further research.
To our knowledge, this is the first study directly comparing SCIT
and SLIT treatments in a mouse model for allergic airways disease
using clinically relevant allergens. To date, experimental studies dis-
secting the mechanisms of allergen immunotherapy or attempting to
enhance its efficacy have focused on a single route of application,
precluding direct comparison of the efficacy of sublingual vs subcu-
taneous administration of allergen extracts for induction of neutraliz-
ing antibodies and suppression of allergic inflammation or lung
function parameters. In agreement with our results, SCIT treatment
with allergen extracts of birch pollen (BP) or recombinant phospholi-
pase A2 (PLA2) induces strong neutralizing antibody responses, even
resulting in protection from anaphylaxis upon subsequent allergen
challenge.30 Interestingly, in the BP-SCIT model, a higher number of
allergen injections were needed to achieve suppression of AHR than
to induce a neutralizing antibody response.31 Experimental mouse
models of HDM-SLIT treatment have rendered variable results
regarding the efficiency of suppressing the different parameters of
allergic airway disease, but generally show limited induction of neu-
tralizing antibody responses, in line with our own results. For
instance, in one study using Dermatophagoides farinae (Der f)
extracts, SLIT treatment had a more pronounced effect on AHR than
on Th2-driven, eosinophilic airway inflammation.32 In contrast, a
study using both Dermatophagoides pteronyssinus (Der p) and Der f
extracts showed a stronger effect on suppression of eosinophilic air-
way inflammation, while AHR was only suppressed at higher doses
of extracts used for SLIT treatment.33 The latter study also reported
limited effect on spIgG antibody titres, although spIgA was markedly
increased. In mouse models of grass pollen SLIT treatment, induction
of a neutralizing antibody response by GP-SLIT treatment is also lim-
ited,20,34 although daily application of lower amounts of GP extract
was able to induce a modest spIgG1 and IgG2a response in
TABLE 1 Overview of parameters of inflammation after SCIT and
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comparison with less frequent application of higher doses of GP
extract.35 In BP driven mouse models of allergic airway disease, SLIT
with BP extracts or rBet v1 dose-dependently suppressed airway
eosinophilia as well as AHR, in the absence of induction of spIgG or
any effect on spIgE responses.36 Overall, the results in other models
for AIT seem to confirm our observations with regard to the modula-
tion of adaptive immune responses by SCIT, as evidenced by induc-
tion of neutralizing antibody responses and suppression of Th2
driven eosinophilia, whilst SLIT has more of an effect on lung func-
tion parameters, but not so much specific antibodies or Th2 cells.
Moreover, the wide variety of allergen extracts used, the differences
in treatment schemes, and the resulting variable outcomes of SCIT
or SLIT treatment on the clinically relevant parameters of airway
inflammation and lung function underscore the added value of our
approach in combining the two application routes in a single mouse
model using the identical allergen extract for efficient comparison on
immunological and translational parameters.
In clinical studies on AIT, the number of studies that directly
compare sublingual vs subcutaneous application of immunotherapy
in the same patient population, and using allergen preparations is
also very limited. In one study, allergic rhinitis patients sensitized to
Phl p were randomized across three treatment groups: SCIT, SLIT,
and sham control treatment and followed up for 15-24 months.8,13
In this carefully conducted study with limited numbers of patients,
SCIT was observed to induce a more rapid and robust change in sp-
IgG4, IgE-blocking factor, and inhibition of facilitated antigen presen-
tation and basophil activation test. SLIT treatment induced a more
rapid and very strong increase in spIgE, while both treatments pre-
vented seasonal induction of spIgE.8 Of note, after 15 months SLIT
and SCIT treatment resulted in similar levels of inhibition of facili-
tated antigen presentation and symptom score as measured by visual
analogue scale. Subsequent analysis of GP-specific T cell responses
up to 24 months into treatment revealed transient induction of IL-
10 producing T cells and suppression of IL-5 producing T cells in
both SLIT- and SCIT-treated patients, although the reduction in IL-5
producing T cells was significantly stronger in SCIT-treated patients
compared to those that had received SLIT treatment.13 SCIT treat-
ment in this clinical study involved the use of Alum as an adjuvant,
in contrast to the SLIT treatment which was free of adjuvantia,
which might have potentiated the immunoglobulin responses
induced by SCIT treatment.37 Notwithstanding these limitations and
the small patient numbers enrolled in this study, it is clear that SCIT
treatment induced immunological changes with faster kinetics and
stronger magnitude compared to SLIT treatment, which mirrors the
findings in our experimental mouse model. In a very recent study,
larger numbers of patients with severe seasonal allergic rhinitis were
randomized in three 2-year treatment arms (SCIT, SLIT, or placebo)
and followed up for nasal symptom score after allergen provocation
up to 1 year after discontinuation of treatment.38 Around 30
patients per treatment arm finished the study, and while SCIT-trea-
ted patients had significantly reduced nasal symptoms scores in year
1 and year 2 of treatment, SLIT treatment only achieved this in year
2 of treatment. After treatment discontinuation, SLIT was not
effective in reducing nasal symptoms scores, underscoring the need
for prolonged treatment periods or optimized allergen vaccines for
SLIT application.38 Interestingly, spIgG4 responses were stronger and
showed faster kinetics in SCIT treatment compared to SLIT, while
SLIT but not SCIT induced an increased spIgE titres, indicating that
the ratio of spIgG over IgE was much higher in SCIT compared to
SLIT, which was also reflected in the early allergic skin response
upon allergen challenge. Our mouse model shows interesting paral-
lels to this clinical study, where SCIT treatment induces a more rapid
(after 1 week of treatment) and a more pronounced induction of
IgG1 compared to SLIT (only after 6 weeks of treatment and with
lower titres). We did not analyse long-term protection by either SCIT
or SLIT treatment after discontinuation of treatment, however.
Recent insight into the relevance of allergen-specific IgG titres over
specific IgE underscores the potential contribution of the neutralizing
antibody response to the clinical benefit of AIT. A recent 3-centre study
assessing the relation between serum levels of spIgE and IgG and symp-
tom score in children with allergic rhinitis and asthma.39 This well-
designed study finds that the ratio of spIgG over IgE was a far better
predictor of being symptomatic than spIgE titres per se, with asthma
and rhinitis being associated with low IgG/IgE ratios. Interestingly, these
authors identify a possible role for IL-10 producing Th cells in this pro-
tective response,39 which is also considered to be a hallmark of success-
ful allergen-specific immunotherapy.40 In light hereof, SLIT treatment
might be more efficacious if higher spIgG/IgE ratios are accomplished
during treatment. In our experimental mouse model, the serum
responses to the allergen challenges in sensitized and SCIT-, SLIT-, or
control-treated mice were measured at day 6 after the allergen chal-
lenge, which is not optimal for the IgE responses. Nevertheless, we
observed a clear induction of the (memory) IgE response mice that did
not receive SCIT or SLIT treatment. Moreover, while we did calculate
ratios of specific IgE over IgG1 as a measure of neutralizing capacity, we
did not measure the affinity of the neutralizing IgG1 antibodies, which
is important to the quality of the neutralizing antibody response.41 Of
note, the increased allergen-specific IgG1 levels in our mouse model
protected against IgE-dependent allergic responses induced by allergen
challenges, without any signs of IgG1-dependent anaphylaxis, which
has been shown previously to occur in the mouse.41,42 Therefore, we
conclude that our experimental mouse model offers a promising plat-
form for further optimization of GP-SLIT therapy to this end.
Our experimental study sought to achieve this by directly compar-
ing SCIT and SLIT treatments in the model using a standardized proto-
col and on the basis of immunological and translational outcome
parameters. We uniquely treat the mice with either SCIT or SLIT after
parenteral immunization with the allergen, which means in the pres-
ence of an immunological memory population. This design also resulted
in some limitations that we need to consider when interpreting our
results. To allow a more accurate interpretation, we included interim
serum bleeds in SLIT-treated mice, enabling the observation that induc-
tion of neutralizing antibody responses by SLIT treatment was delayed
and reduced compared to SCIT treatment in our experimental model.
In addition, measurement of allergen-induced ear swelling as a parame-
ter of an early allergic response was quite variable within the groups,
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precluding in-depth comparison of suppression of the early allergic
response between SCIT and SLIT treatment in the experimental mouse
model. Finally, we have previously shown that, while SCIT treatment in
the mouse model induces a transient increase in FoxP3+ T cells in cir-
culation, the depletion of these cells at the time of allergen challenges
has a rather modest effect on suppression of allergic phenotypes by
SCIT, indicating that regulatory T cells have a relatively limited role in
the mouse model.43 While IL-10 is critical for suppression for allergic
manifestations in allergen immunotherapy mouse models,44 IL-10 pro-
duction by T cells is not.45 The lack of increased IL-10 and TGFb
responses after SCIT and SLIT treatment in the current study is in line
with this. Nevertheless, our experimental mouse model recapitulates
the differences seen in face-to-face comparisons between GP-SCIT
and SLIT in clinical studies, underscoring its relevance as a platform for
testing improvements for SLIT treatment for allergic disease.
The selection of the optimal application route for GP
immunotherapy is not at all trivial, as shown in a recent study explor-
ing the use of intradermal GP immunotherapy for allergic rhinitis,
where treatment had no effect on primary outcome parameters (daily
combined symptom-medication scores), while secondary end-points
such as nasal and asthma symptoms were worsened, with fewer
symptom-free days.46 Although SCIT treatment might be able to
achieve faster and more robust immunological changes, SLIT treat-
ment has been proven to be an effective therapy. For instance, in a
double-blinded RCT in patients with allergic rhinoconjunctivitis, GP-
SLIT treatment was found to induce a significant and durable induc-
tion of neutralizing antibody responses as well as decreased symptom
score up to 2 years after completion of a 3-year treatment period.5
Moreover, a recent meta-analysis comparing SLIT tablets, SLIT drops,
and SCIT injections for GP allergies reported comparable reduction in
symptom scores and supplemental medication use for SLIT tablets
and SCIT injections.6 In addition, in a systematic review on adverse
events reported with SCIT and SLIT treatment for GP allergic rhinitis,
the authors note that, while data are not available for especially older
treatment regimens, SLIT seemed to have a better overall safety pro-
file when compared to SCIT.47 A literature review of the aforemen-
tioned RCT of SLIT treatment for allergic rhinitis to an RCT of SCIT
treatment for allergic rhinitis employing a very similar study design
and the same GP allergen extract reports very similar effect sizes for
both treatment regimens in suppressing nose and eye symptoms.12
Nevertheless, the authors conclude that SCIT might be a more effec-
tive treatment than SLIT at the cost of having a greater risk for sev-
ere side-effects and the need for administration in a specialist clinic,
while SLIT treatment has a greater risk for poor patient adherence.12
Further improvements in SLIT efficacy in modulating immunological
parameters such as the neutralizing antibody response might there-
fore increase its clinical efficacy, although it must be noted that no
direct evidence for a causal relationship between levels of neutraliz-
ing antibodies and clinical efficacy of allergen immunotherapy is avail-
able to date. Our experimental mouse model can be used to test
improvements of SLIT treatment using a validated SCIT treatment
regime as a reference, making this model a valuable translational
research tool for improvement of SLIT efficacy in the future.
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